{"code":0,"message":"成功","totalNum":0,"result":{"docId":"101002026051370002768","docLibId":3,"headLine":"2025年我国药品审批质效双升 ","productCategoryId":"c0030002,c0030021,c0030173,c0030322,c0030363","productCategoryName":"通稿新闻线路,新华网通稿,新媒体专线,新华社客户端,县级融媒体专线","authors":"戴小河","authorsEn":"Dai Xiaohe","authorsId":"daixiaohe","geographyCategoryId":"","columnCategoryId":"<100001><c0030002><c0030002014>,<100004><c0030173><c0030173004>,<100004><c0030322><c23046><c0030322010>,<100004><c0030363><c00303630022>,<c21><c2102><c210201><c0030021>","organizationId":"c0241000","newsCategoryId":"c0270854","content":"　　新华社北京5月13日电（记者戴小河）国家药监局药品审评中心13日发布的《2025年度药品审评报告》显示，2025年我国药品注册申请受理、审结数量稳步增长，创新药获批数量创历史新高，临床急需用药加速上市，药品审评审批体系持续完善，有力保障群众用药需求。","keywords":"药品,创新药","wordCount":576,"languageId":"zh-CN","symbol":"XxjdzbC000041_20260513_CBTFN0.xml","broadcastDate":"2026-05-13 18:41:59","broadcastDateTimestamp":1778668919000,"mediaTypeId":"Text","happenPlace":"","reportPlace":"","tagKeywords":"内分泌,药品申报,国家药监局药品审评中心,13日,药品审评,审批体系,新机制,新靶点,病种新药,药审中心,中医优势,各类药品,用药供给,仿制药,两项数据","photoPlateNum":"","pixelHeight":null,"pixelWidth":null,"duration":null,"guidePrice":0,"previewUrl":null,"playUrl":null,"newsCategoryIdTop":"c0270854","isBought":false,"showPercentVideo":0.5,"isOrdered":false,"isCollected":false,"isViewed":false,"isDownloaded":false,"isLiked":false,"downloadCount":null,"collectedCount":null,"viewedCount":null,"tagJson":"","notionalArea":"","internalName":"中国新闻","issuerDeptId":"","issuerDept":"国内部-总编室","sharelink":null,"docSource":null,"attach":[],"album":null,"ordered":false,"id":"111002026051300006522","collected":false,"viewed":false,"downloaded":false,"liked":false,"bought":false}}